Increased plasma transforming growth factor-beta1 in migraine

Headache. 2005 Oct;45(9):1224-8. doi: 10.1111/j.1526-4610.2005.00246.x.


Background and objectives: Migraine is characterized by the peripheral and central sensitization of pain perceptive neural systems, and neurogenic inflammation is a key step in the development of migraine headache. We focused on transforming growth factor-beta1 (TGF-beta1), which is a multifunctional proinflammatory cytokine. To address the possibility of TGF-beta1 involvement in migraine, we investigated the plasma level of TGF-beta1 in patients with migraine headache during headache-free periods.

Subjects and methods: Sixty-eight subjects with migraine participated: 23 with migraine with aura (MWA) and 45 without aura (MWoA). We recruited 58 healthy subjects without headache as controls. In addition, we examined 12 subjects with episodic tension-type headache. Platelet poor plasma (PPP) was obtained from subjects during headache free-periods. TGF-beta1 levels in PPP were determined by enzyme-linked immunosorbent assay.

Results: The TGF-beta1 level in PPP was 2.62*+/- 0.23 (mean +/- SE) ng/mL in migraine, 2.08 +/- 0.20 ng/mL in tension-type headache, and 1.80 +/- 0.09 ng/mL in controls (P= .007, ANOVA; *P < .01, post hoc tests vs. the controls).

Conclusion: TGF-beta1 in PPP was significantly increased in patients with migraine during headache-free periods. TGF-beta1 may play some role in the development of migraine headache.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Migraine Disorders / blood*
  • Migraine with Aura / blood
  • Migraine without Aura / blood
  • Tension-Type Headache / blood
  • Transforming Growth Factor beta / blood*
  • Transforming Growth Factor beta1


  • TGFB1 protein, human
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1